Publication:
Is driving oxygen flow rate clinically important for nebulizer therapy in patients with COPD?

dc.contributor.authorS. Charoenratanakulen_US
dc.contributor.authorK. Borrirukwaniten_US
dc.contributor.authorW. Satayawiwaten_US
dc.contributor.authorS. Lekuthaien_US
dc.contributor.authorW. Dejsomritrutaien_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-07-04T06:55:51Z
dc.date.available2018-07-04T06:55:51Z
dc.date.issued1995-12-01en_US
dc.description.abstractOur study suggests that the administration of bronchodilator drug via nebulizer powered by flow rate 6 L/min is more suitable in COPD patients. The oxygen flow rates should not be given more than 6 L/min. In this study, we recruited COPD patients in a stable stage, in whom the risk of hyperoxic induced hypercarbia is less than in the acute exacerbation stage. Thus, in acute exacerbation stage of the COPD patients, the rise of carbon-dioxide should be higher. We recommend that the COPD patients should receive bronchodilator drug via the nebulizer, especially in acute exacerbation stage, with oxygen flow rate not more than 6 L/min. The medical personnel must closely observe the clinical signs of the patients to prevent the hazard of carbon-dioxide retention.en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.78, No.12 (1995), 670-677en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-0029552450en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/17349
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029552450&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleIs driving oxygen flow rate clinically important for nebulizer therapy in patients with COPD?en_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0029552450&origin=inwarden_US

Files

Collections